Oded Shoseyov - Evogene Director
| EVGN Stock | ILA 241.10 15.70 6.11% |
Director
Prof. Oded Shoseyov was appointed Director at Evogene Ltd effective November 13, 2018. Prof. Shoseyov work experience includes the following roles world renowned Scientist, Scientific Founder of 12 companies, including Futuragene and Collplant, faculty member of The Hebrew University of Jerusalem and Conductor of research in plant molecular biology protein engineering and nanobiotechnology. Prof. Shoseyov holds a Doctorate of Science degree in Biochemistry from The Hebrew University of Jerusalem. He is the recipient of the Outstanding Scientist Polak Award for 2002, the Kay Award for Innovative and Applied Research in 1999 and 2010 and the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation. since 2018.
| Age | 62 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | (972) 8 946 6724 |
| Web | www.evogene.com |
Evogene Management Efficiency
The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ruth Arnon | Compugen | 86 | |
| Mordechai Keret | Bezeq Israeli Telecommunication | 60 | |
| Sanford Zweifach | Compugen | 60 | |
| Kinneret Savitsky | Compugen | 50 | |
| Zeev Vurembrand | Bezeq Israeli Telecommunication | 66 | |
| Rami Nomkin | Bezeq Israeli Telecommunication | 68 | |
| Amikam Shorer | Bezeq Israeli Telecommunication | 49 | |
| Yair Aharonowitz | Compugen | 73 | |
| Ilan Biran | Bezeq Israeli Telecommunication | 70 | |
| Dov Kotler | Bezeq Israeli Telecommunication | 60 | |
| David Granot | Bezeq Israeli Telecommunication | 71 | |
| Ehud Mezuman | Bezeq Israeli Telecommunication | 62 | |
| Tali Simon | Bezeq Israeli Telecommunication | 48 | |
| Orly Guy | Bezeq Israeli Telecommunication | 56 | |
| Michal Preminger | Compugen | N/A | |
| Amnon Dick | Bezeq Israeli Telecommunication | 64 | |
| Eran Perry | Compugen | N/A | |
| Or Elovitch | Bezeq Israeli Telecommunication | 40 | |
| Ytzhak Edelman | Bezeq Israeli Telecommunication | 64 | |
| Edith Lusky | Bezeq Israeli Telecommunication | 66 | |
| Joshua Shemer | Compugen | 63 | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 |
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | ||
| Assaf Oron, Executive VP Corporate Devel. | ||
| Martin Gerstel, Chairman of the Board | ||
| Oded Shoseyov, Director | ||
| Eyal Leibovitz, CFO | ||
| Yaron Eldad, Chief Officer | ||
| Eyal Ronen, Exec Devel | ||
| Adina Makover, Independent Director | ||
| Adrian Percy, Director | ||
| Sarit Firon, Independent Director | ||
| Sassi Masliah, Exec Devel | ||
| Yuval BenGalim, COO | ||
| Michael Anghel, External Director | ||
| Liat Wejgman, VP HR | ||
| Eran Kosover, Executive Vice President & General Manager Ag-Chemicals | ||
| Ofer CPA, CEO Pres | ||
| Ofer Haviv, President, Chief Executive Officer | ||
| Amos Shachar, Vice President of Project Management | ||
| Ido Dor, Executive Vice President & General Manager Ag-Biologicals | ||
| Sigal Fattal, Executive Officer | ||
| Dotan Borenstein, Chief Ltd | ||
| Nir Arbel, Chief Officer | ||
| Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals | ||
| Leon Recanati, Independent Director | ||
| Alin SelaBrown, Vice President Screening & Validation Systems | ||
| Kinneret Savitsky, Independent Director | ||
| Eli Zangvil, Director | ||
| Eyal Emmanuel, Executive Vice President-R&D | ||
| Assaf Kacen, Chief Operation Officer | ||
| Arnon Heyman, Vice President & General Manager of Ag-Seeds | ||
| Kinneret Savitzky, External Director | ||
| Simcha Sadan, Director | ||
| Alex Taskar, Chief Financial Officer | ||
| Lea Bloom, Director of Administration & Human Resources | ||
| Ziv Kop, Independent Director | ||
| Elran MBA, Chief Ltd |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 3.37 % | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K |
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |